25810948|t|Monoamine reuptake inhibitors in Parkinson's disease.
25810948|a|The motor manifestations of Parkinson's disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters. Despite wide discrepancy in the methodology of the studies reviewed, the following conclusions can be drawn: (1) selective serotonin transporter (SERT), selective noradrenaline transporter (NET), and dual SERT/NET inhibitors are effective against PD depression; (2) selective dopamine transporter (DAT) and dual DAT/NET inhibitors exert an anti-Parkinsonian effect when administered as monotherapy but do not enhance the anti-Parkinsonian actions of L-3,4-dihydroxyphenylalanine (L-DOPA); (3) dual DAT/SERT inhibitors might enhance the anti-Parkinsonian actions of L-DOPA without worsening dyskinesia; (4) triple DAT/NET/SERT inhibitors might exert an anti-Parkinsonian action as monotherapy and might enhance the anti-Parkinsonian effects of L-DOPA, though at the expense of worsening dyskinesia. 
25810948	0	29	Monoamine reuptake inhibitors	Chemical	-
25810948	33	52	Parkinson's disease	Disease	MESH:D010300
25810948	82	101	Parkinson's disease	Disease	MESH:D010300
25810948	103	105	PD	Disease	MESH:D010300
25810948	126	145	dopamine deficiency	Disease	MESH:C567730
25810948	200	202	PD	Disease	MESH:D010300
25810948	328	337	monoamine	Chemical	-
25810948	367	396	monoamine reuptake inhibitors	Chemical	-
25810948	398	403	MAUIs	Chemical	-
25810948	437	443	agents	Chemical	-
25810948	447	449	PD	Disease	MESH:D010300
25810948	551	557	agents	Chemical	-
25810948	635	640	MAUIs	Chemical	-
25810948	644	646	PD	Disease	MESH:D010300
25810948	873	894	serotonin transporter	Gene	6532
25810948	896	900	SERT	Gene	6532
25810948	913	938	noradrenaline transporter	Gene	6530
25810948	955	959	SERT	Gene	6532
25810948	997	999	PD	Disease	MESH:D010300
25810948	1000	1010	depression	Disease	MESH:D003866
25810948	1026	1046	dopamine transporter	Gene	6531
25810948	1048	1051	DAT	Gene	6531
25810948	1062	1065	DAT	Gene	6531
25810948	1095	1107	Parkinsonian	Disease	MESH:D010300
25810948	1176	1188	Parkinsonian	Disease	MESH:D010300
25810948	1200	1228	L-3,4-dihydroxyphenylalanine	Chemical	MESH:D007980
25810948	1230	1236	L-DOPA	Chemical	MESH:D007980
25810948	1248	1251	DAT	Gene	6531
25810948	1252	1256	SERT	Gene	6532
25810948	1291	1303	Parkinsonian	Disease	MESH:D010300
25810948	1315	1321	L-DOPA	Chemical	MESH:D007980
25810948	1340	1350	dyskinesia	Disease	MESH:D004409
25810948	1363	1366	DAT	Gene	6531
25810948	1371	1375	SERT	Gene	6532
25810948	1407	1419	Parkinsonian	Disease	MESH:D010300
25810948	1469	1481	Parkinsonian	Disease	MESH:D010300
25810948	1493	1499	L-DOPA	Chemical	MESH:D007980
25810948	1536	1546	dyskinesia	Disease	MESH:D004409
25810948	Association	MESH:D003866	6530
25810948	Association	MESH:D007980	6532
25810948	Negative_Correlation	MESH:D007980	MESH:D010300
25810948	Association	MESH:D010300	6531
25810948	Association	MESH:D007980	6531
25810948	Association	MESH:D003866	6532

